Sponsors (2)
The bill increases transparency and FDA/FTC oversight of drug and telehealth promotion on social media—likely improving patient safety and exposing deceptive advertising—while creating new compliance costs, enforcement risks, and surveillance/speech/privacy concerns for influencers, providers, manufacturers, and possibly consumers.
Patients (especially those with chronic conditions, Medicare and Medicaid beneficiaries) will be less exposed to misleading paid social-media drug promotions because posts must include key safety/effectiveness information, improving informed decision-making and reducing unsafe use.
Consumers and taxpayers gain greater transparency about industry influence because manufacturer and provider payments to influencers must be reported and publicly posted through Open Payments.
FDA monitoring and analysis of social-media promotion (including use of AI) and coordination with the FTC strengthens oversight and enforcement against deceptive online drug advertising, improving market integrity and compliance.
Broad definitions and rapid platform-speed guidance could chill legitimate personal testimonials and educational content by influencers and patients, restricting online speech and peer-to-peer information sharing.
Social-media influencers and some providers face new civil-penalty exposure for paid posts that lack the statutory 'brief summary', increasing legal and financial risk for individuals and small entities that promote health products.
Manufacturers, providers, and influencers will incur additional reporting and administrative burdens from Open Payments compliance, raising costs that could be passed to consumers or strain small businesses.
Based on analysis of 2 sections of legislative text.
Introduced February 20, 2025 by Richard Joseph Durbin · Last progress February 20, 2025
Makes social media influencers and health care providers legally liable to the U.S. for certain false or misleading promotional communications about prescription drugs, biologics, and certain compounded drugs, and requires companies and providers to report payments tied to such promotion. It directs the HHS Secretary to issue guidance and updated regulations, expands reporting under Open Payments, authorizes FDA market surveillance (including AI tools and platform engagement), requires agency reports to Congress, and provides funding for surveillance from FY2025–2029.